[Fundamental studies of cefoxitin in the field of obstetrics and gynecology].
The concentration of cefoxitin (CFX, Merxin) in dead space exudate was studied in 14 patients following total extirpation of diffuse uterine cervical cancer. A two-compartment model was used for the analysis. The results obtained were as follows: Calculated maximum concentrations of CFX in the pelvic dead space exudate were 26.55 micrograms/ml at 2.11 hours, 31.07 micrograms/mg at 2.01 hours and 51.51 micrograms/ml at 2.10 hours after 1 hour intravenous drip infusions of CFX 2, 3 and 4 g, respectively. These concentrations were higher than the MIC80 of 12.5 micrograms/ml against E. coli and B. fragilis and were maintained for a sufficient period of time. Based on the results of this study, CFX is considered to be an important and valuable drug in the field of obstetrics and gynecology.
D000328:Adult; D000368:Aged; D001424:Bacterial Infections / Q000517:prevention & control; D002440:Cefoxitin / Q000008:administration & dosage / Q000378:metabolism*; D005260:Female; D006801:Humans; D007263:Infusions, Parenteral; D008875:Middle Aged; D010388:Pelvis / Q000378:metabolism*; D013530:Surgical Wound Infection / Q000517:prevention & control; D002583:Uterine Cervical Neoplasms / Q000601:surgery
D002440:Cefoxitin